All In MedTech

Device Trial Radar · NCT07151001

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

Pivotal Trial of Automated AI-based System for Early Diagnosis of Diabetic Retinopathy Using Retinal Color Imaging

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

935

Actual

Start

Jan 1, 2025

Primary completion

Sep 9, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
iHealthScreen IncNot on our public-company list
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH)
First posted
Sep 2, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this pivotal trial, the investigators aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

Conditions

  • Diabetes
  • Diabetic Retinopathy

Interventions

  • No interventionDevice

    No intervention. Evaluate the automated DR screening software.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mtmDR detected (Referable DR) OR mtmDR not detected (non-referable DR)Time frame: 1-year or 2-year

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • iHealthScreen Inc.

    Richmond Hill, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.